

SARS-CoV-2 Sequencing and Variants in Washington State

Washington State Department of Health

November 01, 2023



To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email civil.rights@doh.wa.gov.

Publication Number: 420-316

For more information or additional copies of this report:

Disease Control and Health Statistics
Center for Data Science
1610 NE 150th Street, MS: K17-9
Shoreline, WA 98155

Phone: 206-418-5700 (24-hour contact for local health jurisdictions only)

Email: CommDisEpi@doh.wa.gov

SARS-CoV-2 Sequencing and Variants in Washington State

Washington State Department of Health

November 01, 2023

Next Generation Sequencing (NGS) is a set of laboratory methods that scientists use to scan a viral genome to determine the genome sequence of a virus. A genome sequence of a virus is referred to as its “genomic fingerprint,” and can reveal mutations in a virus that make it unique. Mutations are changes in a genome sequence and occur naturally over time.

Scientists compare viral genomes to better understand how viruses can spread from person to person. NGS technology allows public health officials to detect clusters of cases and monitor new variant viruses. Groups of same-species viruses that share a set of genome mutations are referred to as a lineage. Some variants belonging to specific lineages may have characteristics such as the ability to spread more quickly, cause more severe disease, or impact clinical therapy such as treatment with monoclonal antibodies. These variants may be classified as variants of interest, variants being monitored, variants of concern or variants of high concern.

Throughout this report, we refer to the scientific name of the virus SARS-CoV-2 that causes COVID-19. Sequencing can only be performed on samples that are processed in laboratories and where swabs are stored in liquid that is compatible with sequencing, which means only samples used for molecular tests (such as PCR) can be included. For this reason, this report is limited to confirmed cases only. The genomes that are sequenced and compared are those of the virus, not of humans.

At a glance (data through October 31, 2023)

- During the month of September 2023, **2.8%** of all confirmed molecular COVID-19 cases were sequenced. This number is preliminary and will change over time as additional specimens are received from the previous month.
- **143,060 (9.8%)** COVID-19 cases in Washington state have sequencing information available since January 2021.

CDC currently categorizes variants as Variants of High Consequence (VOHC), Variants of Concern (VOC), Variants of Interest (VOI) and Variants Being Monitored (VBM). There are currently no VOHC or VOI so only VOC and VBM are detailed in this report.

Variants of Concern

Variant	Area first detected	Background	Cumulative Washington cases detected	First detection in Washington*	Most recent detection in Washington*
Omicron (B.1.1.529 and descendant lineages)	South Africa	Early research indicates evidence for increased transmissibility, immune evasion, and lower risk of hospitalization and death, relative to Delta. Approved vaccines are effective at preventing severe disease and death against Omicron variants	76,452	Nov 29, 21	Oct 24, 23

*Detection dates are based on the date a sample is collected, it can take several weeks before a variant result is completed and added to the report

Note: Omicron lineages in this report are defined as below:

Omicron grouping	Inclusion
BA.2	Includes BA.2.X except BA.2.12.1 and BA.2.75.X
BA.2.75	Includes BA.2.75.X except BA.2.75.2 and BA.2.75.5.1
CH.1.1	Includes CH.1.1.X
BA.5	Includes BA.5.X except BF.7 and BA.5.2.6
BQ.1	Includes BQ.1 (Alias of BA.5.3.1.1.1.1.1) except BQ.1.1
XBB	Includes XBB.X except XBB.1.5, XBB.1.9.1, XBB.1.9.2, XBB.1.16, XBB.2.3, FE.1.1
XBB.1.5	Includes XBB.1.5.X except XBB.1.5.1, XBB.1.5.10, XBB.1.5.59, XBB.1.5.68, XBB.1.5.72, EU.1.1
FD.2	Includes FD.2.X
XBB.1.5.1	Includes XBB.1.5.1.X
XBB.1.5.10	Includes XBB.1.5.11.X
XBB.1.5.59	Includes XBB.1.5.59.X
XBB.1.5.68	Includes XBB.1.5.68.X
XBB.1.5.72	Includes XBB.1.5.72.X
EU.1.1	Includes EU.1.1.X
XBB.1.9.1	Includes XBB.1.9.1.X
XBB.1.9.2	Includes XBB.1.9.2.X
EG.5	Includes EG.5.X
XBB.2.3	Includes XBB.2.3.X except XBB.2.3.8
FE.1.1	Includes FE.1.1.X
XBB.1.16	Includes XBB.1.16.X except XBB.1.16.1, XBB.1.16.6, XBB.1.16.15
XBB.1.16.1	Includes XBB.1.16.1.X
XBB.1.16.6	Includes XBB.1.16.6.X
XBB.1.5.72	Includes XBB.1.5.72.X
XBB.1.5.59	Includes XBB.1.5.59.X
FL.1.5.1	Includes FL.1.5.1.X
XBB.1.5.70	Includes XBB.1.5.70.X
EG.6.1	Includes EG.6.1.X
XBB.1.16.11	Includes XBB.1.16.11.X



Omicron grouping	Inclusion
GE.1	Includes GE.1.X
XBB.1.42.2	Includes XBB.1.42.2.X
HF.1	Includes HF.1.X
XBB.1.16.15	Includes XBB.1.16.15.X
HV.1	Includes HV.1.X
GK.2	Includes GK.2.X
GK.1.1	Includes GK.1.1.X
HK.3	Includes HK.3.X

Variants Being Monitored


Variant	Area first detected	Cumulative Washington cases detected	First detection in Washington*	Most recent detection in Washington*
Alpha (B.1.1.7)	United Kingdom	10,338	Jan 07, 21	Sep 08, 21
Beta (B.1.351)	South Africa	282	Jan 29, 21	Jun 29, 21
Delta (B.1.617.2 and AY lineages)	India	38,826	Apr 03, 21	Sep 02, 22
Epsilon (B.1.427 / B.1.429)	California	4,191	Dec 11, 20	Jun 24, 21
Eta (B.1.525)	New York	92	Feb 02, 21	Jun 08, 21
Gamma (P.1)	Brazil	2,498	Feb 06, 21	Dec 02, 21
Iota (B.1.526)	New York	933	Jan 21, 21	Aug 20, 21
Kappa (B.1.617.1)	India	46	Mar 22, 21	Jun 14, 21
Mu (B.1.621)	Colombia	219	Apr 09, 21	Dec 20, 21
Zeta (P.2)	Brazil	45	Jan 18, 21	Apr 20, 21

*Detection dates are based on the date a sample is collected, it can take several weeks before a variant result is completed and added to the report

Epidemiologic curve of variants being monitored and variants of concern by week of specimen collection date from January 01, 2021 to October 20, 2023




Epidemiologic curve of variants being monitored and variants of concern by week of specimen collection date from May 01, 2023 to October 20, 2023



- The above graphs show the total number of variants detected by the week the specimen was collected from a patient.
- Sequencing can be performed on stored patient specimens at any time, so these numbers may change as additional specimens are sequenced.
- This graph shows all specimens sequenced, including specimens sequenced during outbreaks and other targeted sequencing efforts.
- “Other Omicron “ includes B.1.1.529, BA.1.X and BA.3.X sublineages

Number of specimens sequenced, and percent of Washington State confirmed COVID-19 cases that have been sequenced by specimen collection date from January 2021 through October 2023.





- Samples are not sequenced for every confirmed COVID-19 case. The above graph shows the total number of specimens sequenced (gray bars) and the percent of all confirmed cases (blue line) that have had sequencing performed each month. Data from the previous month may still be incomplete.
- Sequencing can be performed on stored specimens at any time, so numbers from past months may change if stored specimens are sequenced.

SARS-CoV-2 Lineages Circulating in Washington State

The graph below shows the change in proportion of select SARS-CoV-2 lineages by time period. A viral lineage is a group of viruses that descend from a common ancestor with shared genetic characteristics, allowing them to be grouped together. Since this figure represents the share of all sequences that a particular lineage represents, as the proportion of sequences assigned to one lineage increases, the proportion of sequences assigned to other lineages will decrease.


NOTE: The data on this graph come from cases that marked as “Baseline surveillance” in GISAID. Cases sequenced because they were part of an outbreak or were otherwise manually selected for sequencing are excluded, as this could cause a lineage to appear over represented.



The chart above shows the proportions of the most common SARS-CoV-2 lineages circulating in Washington grouped in two-week intervals. Proportions are calculated using data which are subject to change over time and will be updated as more data becomes available, including data from prior time periods. **Due to the time it takes to complete sequencing, the most recent time period is based on a very small number of sequences and likely to be adjusted over time.**

To see the national trends, visit the CDC's [variant proportions page](#).


The figures below show the current number of variants of concern (VOC) detected by county of home address since four months prior; data is from the Washington Disease Reporting System (WDRS).




Geographic Coverage of Sequencing

Efforts are made to sequence specimens from all geographic areas of Washington State. The number of sequences and the percent of cases sequenced vary based on several factors including number of cases in that region and which laboratories conduct the majority of testing in each locality.

The map below shows the number of specimens sequenced by county of home address since January 1, 2021.



The map below shows the percent of COVID-19 cases with at least one specimen sequenced by county of home address since January 1, 2021.



The hospitalization table below includes sequencing data since January 1, 2021 sorted by total number of cases per variant and does not account for factors that can influence hospitalization rates such as age and vaccination status, which may be different across variants. This means that hospitalization rates are not necessarily comparable between variants.

Hospitalizations and deaths by variant, sorted by total case count

Variant	Percent cases who were hospitalized	Cases who were hospitalized per 100,000	Cases who died from COVID-19	Total cases	Percent of hospitalized cases who died from COVID-19
Delta	4.3%	4,271	1.3%	38,725	17.2%
BA.5	2.1%	2,101	0.4%	17,750	9.4%
BA.2	1.2%	1,167	0.2%	13,798	8.1%
BA.1	1.2%	1,159	0.3%	12,335	14.7%
BA.1.1	2.3%	2,349	0.8%	11,324	14.7%
Alpha	3.4%	3,443	0.6%	10,311	12.7%
BA.2.12.1	1.8%	1,777	0.3%	6,810	9.9%
Other	2.6%	2,588	0.8%	5,293	16.8%
Epsilon	2.6%	2,588	0.7%	4,134	16.8%
XBB.1.5	4%	4,049	0.4%	3,902	3.2%
BQ.1.1	2.7%	2,657	0.2%	3,011	6.2%
Gamma	6.8%	6,844	1.8%	2,484	17.6%
BQ.1	2%	2,017	0.2%	1,834	5.4%
BA.4	1.9%	1,874	0.3%	1,441	3.7%
Iota	3.2%	3,226	1.3%	930	30%
BA.4.6	2.9%	2,890	0.6%	692	5%
BF.7	3.2%	3,195	0.8%	532	23.5%
XBB	2.4%	2,364	0%	423	0%
BN.1	1.4%	1,351	0.3%	296	25%
EG.5	13.7%	13,746	0.7%	291	0%
Beta	7.1%	7,117	1.1%	281	15%
XBB.1.16	8.3%	8,333	0.4%	252	0%
Mu	2.8%	2,752	1.8%	218	33.3%
BA.2.75	1.1%	1,070	0%	187	0%
XBB.2.3	4.4%	4,396	0.5%	182	0%
XBB.1.9.1	8.7%	8,671	0%	173	0%

Variant	Percent cases who were hospitalized	Cases who were hospitalized per 100,000	Cases who died from COVID-19	Total cases	Percent of hospitalized cases who died from COVID-19
BA.5.2.6	2.4%	2,367	1.2%	169	50%
CH.1.1	5.9%	5,882	0%	153	0%

Age distribution by variant, sorted by total case count

Variant	Age 0-19	Age 20-34	Age 35-49	Age 50-64	Age 65-79	Age 80+	Unknown	Total cases
Delta	23%	29%	23%	15%	8%	2%	0%	38,725
BA.5	12%	28%	26%	20%	12%	3%	0%	17,750
BA.2	19%	32%	24%	15%	8%	2%	0%	13,798
BA.1	24%	33%	23%	13%	5%	1%	0%	12,335
BA.1.1	24%	30%	22%	14%	7%	2%	0%	11,324
Alpha	27%	32%	23%	13%	3%	1%	0%	10,311
BA.2.12.1	15%	32%	24%	17%	10%	3%	0%	6,810
Other	24%	29%	24%	16%	5%	2%	0%	5,293
Epsilon	25%	31%	24%	14%	4%	1%	0%	4,134
XBB.1.5	13%	27%	26%	19%	12%	3%	0%	3,902
BQ.1.1	13%	26%	27%	19%	11%	3%	0%	3,011
Gamma	22%	35%	24%	12%	4%	3%	0%	2,484
BQ.1	12%	27%	26%	20%	12%	3%	0%	1,834
BA.4	17%	31%	26%	16%	8%	2%	0%	1,441
Iota	25%	33%	25%	12%	4%	1%	0%	930
BA.4.6	13%	31%	24%	16%	13%	2%	0%	692
BF.7	10%	27%	23%	23%	13%	5%	0%	532
XBB	10%	31%	26%	22%	9%	2%	0%	423
BN.1	11%	24%	30%	18%	13%	3%	0%	296
EG.5	8%	19%	25%	17%	21%	7%	0%	291
Beta	28%	34%	21%	12%	3%	0%	0%	281
XBB.1.16	10%	21%	27%	18%	17%	6%	0%	252
Mu	22%	37%	22%	11%	6%	1%	0%	218
BA.2.75	10%	25%	32%	18%	14%	1%	0%	187
XBB.2.3	13%	15%	24%	23%	21%	5%	0%	182
XBB.1.9.1	13%	19%	25%	22%	15%	5%	0%	173
BA.5.2.6	11%	30%	26%	15%	15%	2%	0%	169

Variant	Age 0-19	Age 20-34	Age 35-49	Age 50-64	Age 65-79	Age 80+	Unknown	Total cases
CH.1.1	10%	31%	24%	15%	17%	4%	0%	153

*Other includes all variant viruses that are not categorized as VOC or VBM

The following clinical laboratories have contributed specimens for sequencing:

Aegis Sciences Corporation
Allenmore Hospital Laboratory
Altius Institute for Biomedical Sciences
Atlas Genomics
Avero Diagnostics
BioReference Laboratories Inc.
Cascade Valley Hospital
Central Washington Hospital
Columbia Basin Hospital
Curative Labs Inc.
Dayton General Hospital
Deaconess Hospital
Diatherix Laboratories
Dynacare Northwest Inc.
East Adams Rural Hospital
Everett Clinic Microbiology
Evergreen Healthcare
Ferry County Hospital
FidaLab
Forks Community Hospital
Fulgent Genetics
Gravity Diagnostics, LLC
Harborview Medical Center
Healthquest Esoterics
Helix/Illumina
Incyte Diagnostics Spokane
Infinity Biologix

Interpath Laboratory
Jefferson Healthcare
Kaiser Permanente Washington Health Research Institute
Labcorp
Laboratories Northwest
Laboratory Corporation of America
Legacy Laboratory
Magnolia Diagnostics, LLC
Mann-Grandstaff VA Medical Center
Mason General Hospital Laboratory
Mid Valley Hospital
Molecular Testing Labs
MultiCare
Avero Diagnostics
OHSU Lab Services Molecular Microbiology Lab
Olympic Medical Center
Overlake Hospital
PeaceHealth
Polyclinic
Premier Medical Laboratory
Providence Medical Group
Public Health Seattle-King County Laboratory
Quest Diagnostics Incorporated
Samaritan Hospital Lab
Seattle & King County Public Health Lab
Seattle Children's Hospital
Seattle Flu Study
Skagit Valley Hospital Laboratory
St. Francis Hospital

St. Joseph Medical Center Microbiology
St. Michael Medical Center Laboratory
Swedish Medical Center
Tacoma General Hospital
The Vancouver Clinic
Tomorrow's Health, LLC
TridentCare Laboratory
TridentCare Laboratory
University of Washington Virology Lab
Virginia Mason Franciscan Health Microbiology
Washington State Department of Health Public Health Laboratories

The following labs have reported sequencing data that is included in this report:

Aegis Laboratory
Altius Institute for Biomedical Research
Atlas Genomics
Boise VA Medical Center
Centers for Disease Control and Prevention
Curative
Flow Diagnostics
Fulgent Genetics
Ginkgo Bioworks Clinical Laboratory
Gravity Diagnostics, LLC
Gritman Medical Center
Grubaugh Lab
Helix Laboratories
Idaho Bureau of Laboratories
Infinity Biologix
Institute for Systems Biology

Kaiser Permanente
Laboratory Corporation of America
Montana Public Health Laboratory
Naval Health Research Center
Oregon SARS-CoV-2 Genome Sequencing Center
Oregon State Public Health Laboratory
Providence St. Joseph Health Molecular Genomics Laboratory
Quest Diagnostics
Seattle Flu Study
The Jackson Laboratory
The Loring Laboratory
United States Army Medical Research Institute of Infectious Diseases
University of Washington Virology Lab
Washington State Department of Health Public Health Laboratories
